Uncategorized

Kailera plans IPO for Phase 3 obesity drug from Hengrui

Kailera plans IPO for Phase 3 obesity drug from Hengrui

Published

1 week ago

on

One of biotech’s best-funded startups plans to go public, as it seeks to take its obesity portfolio into a market crowded by Eli Lilly, Novo Nordisk and other next-generation obesity contenders.

Kailera Therapeutics​ ​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version